L’hémoglobinurie paroxystique nocturne est une maladie liée à une mutation somatique entraînant l’expansion de clones cellulaires déficients pour des. Site Internet de la filière de santé maladies rares MaRIH, Publications Aplasie médullaire/Hémoglobinurie paroxystique nocturne/Anémie de Fanconi. Many translated example sentences containing “hémoglobinurie paroxystique nocturne” – English-French dictionary and search engine for English translations.

Author: Kikasa Virg
Country: Timor Leste
Language: English (Spanish)
Genre: Relationship
Published (Last): 5 May 2005
Pages: 338
PDF File Size: 7.73 Mb
ePub File Size: 10.13 Mb
ISBN: 610-6-29700-387-8
Downloads: 82126
Price: Free* [*Free Regsitration Required]
Uploader: Malakus

Publications Aplasie médullaire/Hémoglobinurie paroxystique nocturne/Anémie de Fanconi

Boyer T et al. French Society of Haematology. In classic PNH, recent studies have focused on inhibiting the complement cascade with encouraging clinical results using eculizumab, a C5-inhibitor humanized monoclonal antibody. Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: Cyclosporin A versus antilymphocytic globulin in severe aplastic anaemia. From earlier descriptions, the clinical polymorphism of PNH has been recognized by two presentations; one form, predominantly haemolytic without overt marrow failure, referred to classic PNH and the other one, with marrow failure, was often described as the aplastic anemia PNH syndrome AA-PNH.

Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.


Characterization of T-cell repertoire of hmpglobinurie bone marrow in immune-mediated aplastic anemia: Transplant results in adults with Fanconi anaemia. A collection of writing tools that cover paroyxstique many facets of English and French grammar, style and usage. Recurrent thrombotic events remains even now associated with bad prognosis, whatever the form of the disease.

The role of antilymphocyte globulin in the treatment of chronic acquired bone marrow failure. First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia.


Association of aplastic anaemia and lymphoma: Top of the page – Article Outline. Nouveau cas clinique “Amylose AL” Testez vos connaissances. Benajiba L et al. Change the order of display of the official languages of Canada English first French first Option to display the non-official languages Spanish or Portuguese Neither Spanish Portuguese Display definitions, contexts, etc.

In which subject field? Language Portal of Canada Access a collection of Canadian resources on all aspects of English and French, including quizzes.

The treatment of severe acquired aplastic anemia. Unrelated stem cell transplantation for severe acquired aplastic anemia: Glossaries and vocabularies Access Translation Bureau glossaries and vocabularies.


L’hémoglobinurie paroxystique nocturne – EM|consulte

Paroxysttique phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Sicre de Fontbrune et al. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria PNH. Access to the text HTML. An unknown cause of thrombosis?

Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: Outcome of patients treated In-vivo dominant immune responses in aplastic anaemia: Aplastic anemia in the elderly: Gene expression profiling in CD34 cells to identify differences between aplastic anemia nocture and healthy volunteers.

A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: The disease is diagnosed with haemolytic anemia, marrow failure or episodes of venous thrombosis.